Literature for evogliptin (S09.003 inhibitor)

Summary Literature

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

    2011
  1. Cho,J.M., Jang,H.W., Cheon,H., Jeong,Y.T., Kim,D.H., Lim,Y.M., Choi,S.H., Yang,E.K., Shin,C.Y., Son,M.H., Kim,S.H., Kim,H.J. and Lee,M.S.
    A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis
    Diabetes Res Clin Pract91, 72-79. PubMed  Europe PubMed DOI  I
  2. Kim,H.J., Kwak,W.Y., Min,J.P., Lee,J.Y., Yoon,T.H., Kim,H.D., Shin,C.Y., Kim,M.K., Choi,S.H., Kim,H.S., Yang,E.K., Cheong,Y.H., Chae,Y.N., Park,K.J., Jang,J.M., Choi,S.J., Son,M.H., Kim,S.H., Yoo,M. and Lee,B.J.
    Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Bioorg Med Chem Lett21, 3809-3812. PubMed  Europe PubMed DOI  I